─New evidence shows that the anti-inflammatory and anti-fibrotic effects of CM-101 are of great importance in inflammatory lung diseases─
Tel Aviv, Israel, November 9, 2022 /PRNewswire/ — Chemomab Therapeutics, Ltd. CMMB (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs, announced that clinical data presented today demonstrated that CM-101 is safe and well-tolerated and a reduction in biomarkers associated with pneumonia and fibrogenesis in a clinical trial in patients hospitalized with a lung injury caused by COVID-19. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with profibrotic and proinflammatory effects. It is in development for the treatment of fibro-inflammatory diseases including primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
The presentation, Treatment with CM-101-reduced inflammatory and fibrotic biomarkers in patients with COVID-19-related lung injurywas created by Chemomab co-founder and Chief Scientific Officer Dr. Adi Mor at the Union World Conference on Lung Health 2022.
Some of the mechanisms underlying pneumonia secondary to COVID-19 infection are similar to those observed in chronic diseases involving pneumonia and fibrosis, and this study was initiated by a physician/researcher who treated patients with systemic sclerosis and other rheumatologic …
